
Opinion|Videos|May 1, 2025
Optimizing Genomic Testing in Breast Cancer: Strategies for Community Practitioners
Panelists discuss how community practitioners face challenges with genomic testing due to working across multiple hospitals with different medical oncology groups who may have varying preferences for assays, emphasizing the importance of communication, established algorithms, and leveraging partnerships with testing companies.
Advertisement
Practical Implementation and Community Practice Challenges
Main Discussion Topics:
- Challenges faced by community practitioners regarding genomic testing
- Implementation of reflex testing strategies based on pathological criteria
- Billing, reimbursement, and ordering logistics in different practice settings
Key Points for Physicians:
- Community practitioners often work across multiple hospitals with different medical oncology groups who may have different testing preferences.
- Electronic portal-based ordering systems and electronic medical record integration improve workflow efficiency.
- Relationships with testing companies can help address reimbursement and coding issues.
Notable Insights:
- Some institutions implement reflex testing criteria based on T and N staging and patient age to improve efficiency.
- Testing companies can be valuable partners in ensuring appropriate coding and test selection.
Clinical Significance: Successful implementation of genomic testing in community settings requires robust communication systems, clear algorithms, and attention to billing/reimbursement considerations to ensure appropriate test utilization.
Advertisement
Related to this article

Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.

A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.

The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.

The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.

Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.

An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.

Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
4
Dr Hurvitz on SERENA-6 and Weighing an Early Switch to Camizestrant in Breast Cancer
5

